Cargando…

Progress in Anticancer Drug Development Targeting Ubiquitination-Related Factors

Ubiquitination is extensively involved in critical signaling pathways through monitoring protein stability, subcellular localization, and activity. Dysregulation of this process results in severe diseases including malignant cancers. To develop drugs targeting ubiquitination-related factors is a hot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Qianqian, Zhang, Weiwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737479/ https://www.ncbi.nlm.nih.gov/pubmed/36499442 http://dx.doi.org/10.3390/ijms232315104

Ejemplares similares

The ubiquitin-proteasome system: A novel target for anticancer and anti-inflammatory drug research
por: Ostrowska, Halina
Publicado: (2008)

Ubiquitin–proteasome system (UPS) as a target for anticancer treatment
por: Park, Jinyoung, et al.
Publicado: (2020)

Progressive study of effects of erianin on anticancer activity
por: Zhang, Yuying, et al.
Publicado: (2019)

Drug Development Targeting the Ubiquitin–Proteasome System (UPS) for the Treatment of Human Cancers
por: Zhang, Xiaonan, et al.
Publicado: (2020)

Anticancer Drug Development
por: Loadman, P
Publicado: (2002)

Targeted Delivery Methods for Anticancer Drugs
por: Veselov, Valery V., et al.
Publicado: (2022)

Drugging the undruggables: exploring the ubiquitin system for drug development
por: Huang, Xiaodong, et al.
Publicado: (2016)

Handbook of Anticancer Drug Development
por: Subramanian, B
Publicado: (2004)

Progress of small ubiquitin-related modifiers in kidney diseases
por: Li, Ou, et al.
Publicado: (2019)

Monoamine Oxidase (MAO) as a Potential Target for Anticancer Drug Design and Development
por: Aljanabi, Reem, et al.
Publicado: (2021)

The role of ubiquitination in tumorigenesis and targeted drug discovery
por: Deng, Lu, et al.
Publicado: (2020)

Anticancer drug discovery by targeting cullin neddylation
por: Yu, Qing, et al.
Publicado: (2020)

Emerging drug development technologies targeting ubiquitination for cancer therapeutics
por: Veggiani, Gianluca, et al.
Publicado: (2019)

MicroRNA as an Important Target for Anticancer Drug Development
por: Fu, Zhiwen, et al.
Publicado: (2021)

The Role of Ubiquitination in Regulating Embryonic Stem Cell Maintenance and Cancer Development
por: Wang, Dian, et al.
Publicado: (2019)

DNA topoisomerases as molecular targets for anticancer drugs
por: Buzun, Kamila, et al.
Publicado: (2020)

NSAIDs: Old Drugs Reveal New Anticancer Targets
por: Piazza, Gary A., et al.
Publicado: (2010)

Progestins as Anticancer Drugs and Chemosensitizers, New Targets and Applications
por: Fedotcheva, Tatiana A., et al.
Publicado: (2021)

Advanced and Innovative Nano-Systems for Anticancer Targeted Drug Delivery
por: Tang, Lu, et al.
Publicado: (2021)

The roles of E3 ubiquitin ligases in cancer progression and targeted therapy
por: Sampson, Chibuzo, et al.
Publicado: (2023)

An Overview of the Recent Development of Anticancer Agents Targeting the HIF-1 Transcription Factor
por: Shirai, Yukari, et al.
Publicado: (2021)

Linking Late Endosomal Cholesterol with Cancer Progression and Anticancer Drug Resistance
por: Nguyen, Mai K. L., et al.
Publicado: (2022)

Roles of RNA Methylations in Cancer Progression, Autophagy, and Anticancer Drug Resistance
por: Jo, Hyein, et al.
Publicado: (2023)

Lysophosphatidic Acid: Promoter of Cancer Progression and of Tumor Microenvironment Development. A Promising Target for Anticancer Therapies?
por: Aiello, Sistiana, et al.
Publicado: (2021)

Anticancer Alkaloids from Trees: Development into Drugs
por: Isah, Tasiu
Publicado: (2016)

The role of E3 ubiquitin ligases in the development and progression of glioblastoma
por: Humphreys, Luke M., et al.
Publicado: (2021)

Genetic Interactions of STAT3 and Anticancer Drug Development
por: Fang, Bingliang
Publicado: (2014)

Epothilones as Natural Compounds for Novel Anticancer Drugs Development
por: Villegas, Cecilia, et al.
Publicado: (2023)

Breaking the Bottleneck in Anticancer Drug Development: Efficient Utilization of Synthetic Biology
por: Wang, Haibo, et al.
Publicado: (2022)

DNA-Binding Anticancer Drugs: One Target, Two Actions
por: Baguley, Bruce C., et al.
Publicado: (2021)

Targeting TRIP13 for overcoming anticancer drug resistance (Review)
por: Zhao, Liwen, et al.
Publicado: (2023)

TBX2 and TBX3: The special value for anticancer drug targets
por: Lu, Juan, et al.
Publicado: (2010)

Clinical anticancer drug development: targeting the cyclin-dependent kinases
por: Benson, C, et al.
Publicado: (2005)

Progress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery Systems
por: Jiang, Feng, et al.
Publicado: (2015)

The Anticancer Drugs
por: Wilkinson, P.
Publicado: (1980)

Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets
por: Bedford, Lynn, et al.
Publicado: (2010)

Canonical TGFβ Signaling and Its Contribution to Endometrial Cancer Development and Progression—Underestimated Target of Anticancer Strategies
por: Zakrzewski, Piotr K.
Publicado: (2021)

Role of Reductive versus Oxidative Stress in Tumor Progression and Anticancer Drug Resistance
por: Chun, Kyung-Soo, et al.
Publicado: (2021)

Developing Targeted Therapies That Exploit Aberrant Histone Ubiquitination in Cancer
por: Jeusset, Lucile M-P, et al.
Publicado: (2019)

The Potential of Senescence as a Target for Developing Anticancer Therapy
por: Jo, Hyein, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c3o211kjeonin9pjeh1iq3u2bs